Three candidates for US FDA approval are using real-world evidence as part of the efficacy argument, illustrating some of the most common ways to RWE in applications.
In keeping with FDA’s history of approvals incorporating RWE of efficacy, all of the applications target rare diseases: Friedreich’s ataxia...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?